Association between tumor necrosis factor alpha gene polymorphisms and multiple myeloma risk: an updated meta-analysis

References

• Dhodapkar MV, Borrello I, Cohen AD, et al. Hematologic malignancies: plasma cell Disorders. Am Soc Clin Oncol Educ Book. 2017;37:561–568. doi: 10.14694/EDBK_175546
   PubMedGoogle Scholar
• Tang S, Cheng B, Zhe N, et al. Histone deacetylase inhibitor BG45-mediated HO-1 expression induces apoptosis of multiple myeloma cells by the JAK2/STAT3 pathway. Anticancer Drugs. 2018;29:61–74. doi: 10.1097/CAD.0000000000000568
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;88:719–2734.
   Web of Science ®Google Scholar
• Angtuaco EJC, Fassas ABT, Walker R, et al. Multiple myeloma: Clinical review and Diagnostic Imaging1. Radiology. 2004;231:11–23. doi: 10.1148/radiol.2311020452
   PubMed Web of Science ®Google Scholar
• Stellrecht CM, Gandhi V. Myeloma antioxidant status: the good, the bad and the reactive. Leuk Lymphoma. 2009;50:691–693. doi: 10.1080/10428190902856832
   PubMed Web of Science ®Google Scholar
• Becker N. Epidemiology of multiple myeloma. Berlin/Heidelberg: Springer; 2011; p. 1–15.
   Google Scholar
• Munshi NC, Avetloiseau H. Genomics in multiple myeloma. Clin Cancer Res. 2011;17:1234–1242. doi: 10.1158/1078-0432.CCR-10-1843
   PubMed Web of Science ®Google Scholar
• Chakraborty B, Vishnoi G, Gowda SH, et al. Interleukin-6 gene-174 G/C promoter polymorphism and its association with clinical profile of patients with multiple myeloma. Asia-Pac J Clin Oncol. 2017;13:e402–e407. doi: 10.1111/ajco.12290
   PubMed Web of Science ®Google Scholar
• Kasamatsu T, Kimoto M, Takahashi N, et al. IL17A and IL23R gene polymorphisms affect the clinical features and prognosis of patients with multiple myeloma. Hematol Oncol. 2018;36:196–201. doi: 10.1002/hon.2469
   PubMed Web of Science ®Google Scholar
• Basmaci C, Pehlivan M, Tomatir AG, et al. Effects of TNFalpha, NOS3, MDR1 gene polymorphisms on clinical parameters, prognosis and survival of multiple myeloma cases. Asian Pac J Cancer Prev. 2016;17:1009–1014. doi: 10.7314/APJCP.2016.17.3.1009
   PubMedGoogle Scholar
• Chan KM, Siegel RM, Lenardo MJ. Signaling by the TNF receptor superfamily and T cell homeostasis. Immunity. 2000;13:419–422. doi: 10.1016/S1074-7613(00)00041-8
   PubMed Web of Science ®Google Scholar
• Reiterer G, Toborek MB. Tumour necrosis factor gene polymorphisms in lymphoproliferative disease. Leuk Lymphoma. 2000;38:547–552. doi: 10.3109/10428190009059274
   PubMed Web of Science ®Google Scholar
• Sawamura M, Murakami H, Tsuchiya J. Tumor necrosis factor-alpha and interleukin 4 in myeloma cell precursor differentiation. Leuk Lymphoma. 1996;21:31–36. doi: 10.3109/10428199609067576
   PubMed Web of Science ®Google Scholar
• Neben K, Mytilineos J, Moehler TM, et al. Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. Blood. 2002;100:2263–2265.
   PubMed Web of Science ®Google Scholar
• Jurišić V, Čolović M. Correlation of sera TNF-α with percentage of bone marrow plasma cells, LDH, β2-microglobulin, and clinical stage in multiple myeloma. Med Oncol. 2002;19:133–139. doi: 10.1385/MO:19:3:133
   PubMed Web of Science ®Google Scholar
• Liu YH, Peng Z, Song WG, et al. Polymorphisms of tumor necrosis factor and susceptibility to multiple myeloma. Chin J Cancer Prev Treat. 2012;19:1696–1699.
   Google Scholar
• Li B, Wang XD, Sun X, et al. Lack of association between TNF-α promoter polymorphisms and multiple myeloma: a meta-analysis. Leuk Res. 2013;37:50–57. doi: 10.1016/j.leukres.2012.08.027
   PubMed Web of Science ®Google Scholar
• Wells GA, Shea BJ, O’Connell D, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analysis. Appl Eng Agric. 2014;18:727–734.
   Google Scholar
• Schaid DJ, Jacobsen SJ. Biased tests of association: comparisons of allele frequencies when departing from Hardy-Weinberg proportions. Am J Epidemiol. 1999;149:706–711. doi: 10.1093/oxfordjournals.aje.a009878
   PubMed Web of Science ®Google Scholar
• Liu T, Xu QE, Zhang CH, et al. Occupational exposure to methylene chloride and risk of cancer: a meta-analysis. Cancer Causes Control. 2013;24:2037–2049. doi: 10.1007/s10552-013-0283-0
   PubMed Web of Science ®Google Scholar
• Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127:820–826. doi: 10.7326/0003-4819-127-9-199711010-00008
   PubMed Web of Science ®Google Scholar
• Feng RN, Zhao C, Sun CH, et al. Meta-analysis of TNF 308 G/A polymorphism and type 2 diabetes mellitus. PLoS One. 2011;6:e18480. doi: 10.1371/journal.pone.0018480
   PubMed Web of Science ®Google Scholar
• Minder C, Egger M, Smith GD, et al. Bias in meta-analysis detected by a simple, graphical test. Br Med J. 1997;315:629–634. doi: 10.1136/bmj.315.7109.629
   PubMed Web of Science ®Google Scholar
• Aykut V, Kirgiz A, Gül AB, et al. Comparison of pre-incision and single-stepped clear corneal incision in phacoemulsification surgery. Eur Rev Med Pharmacol Sci. 2014;18:1698–1703.
   PubMed Web of Science ®Google Scholar
• Au WY, Fung A, Wong KF, et al. Tumor necrosis factor alpha promoter polymorphism and the risk of chronic lymphocytic leukemia and myeloma in the Chinese population. Leuk Lymphoma. 2006;47:2189–2193. doi: 10.1080/10428190600758645
   PubMed Web of Science ®Google Scholar
• Davies FE, Rollinson SJ, Rawstron AC, et al. High-producer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have an improved progression-free survival after treatment. J Clin Oncol. 2000;18:2843–2851. doi: 10.1200/JCO.2000.18.15.2843
   PubMed Web of Science ®Google Scholar
• Martino A, Buda G, Maggini V, et al. Could age modify the effect of genetic variants in IL6 and TNF-α genes in multiple myeloma? Leuk Res. 2012;36:594–597. doi: 10.1016/j.leukres.2012.02.009
   PubMed Web of Science ®Google Scholar
• Yakupova EV, Grinchuk OV, Kalimullina DK, et al. Molecular genetic analysis of the Interleukin 6 and tumor necrosis factor α gene polymorphisms in multiple myeloma. Mol Biol. 2003;37:358–361. doi: 10.1023/A:1024227008451
   Web of Science ®Google Scholar
• Lu ZM, Zhang Q, Zu Y, et al. Polymorphisms of TNF-alpha and promoter genes in multiple myeloma. Chin J Intern Med. 2007;46:767–768.
   Google Scholar
• Morgan GJ, Adamson PJ, Mensah FK, et al. Haplotypes in the tumour necrosis factor region and myeloma. Br J Haematol. 2005;129:358–365. doi: 10.1111/j.1365-2141.2005.05467.x
   PubMed Web of Science ®Google Scholar
• Brown EE, Lan Q, Zheng T, et al. Common variants in genes that mediate immunity and risk of multiple myeloma. Int J Cancer. 2007;120:2715–2722. doi: 10.1002/ijc.22618
   PubMed Web of Science ®Google Scholar
• Du J, Yuan ZG, Zhang CY, et al. Role of the TNF-α promoter polymorphisms for development of multiple myeloma and clinical outcome in thalidomide plus dexamethasone. Leuk Res. 2010;34:1453–1458. doi: 10.1016/j.leukres.2010.01.011
   PubMed Web of Science ®Google Scholar
• Kadar K, Kovacs M, Karadi I, et al. Polymorphisms of TNF-alpha and LT-alpha genes in multiple myeloma. Leuk Res. 2008;32:1499–1504. doi: 10.1016/j.leukres.2008.03.001
   PubMed Web of Science ®Google Scholar
• Zheng CY, Huang DR, Bergenbrant S, et al. Interleukin 6, tumour necrosis factor α, interleukin 1β and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma. Br J Haematol. 2000;109:39–45. doi: 10.1046/j.1365-2141.2000.01963.x
   PubMed Web of Science ®Google Scholar
• Sati HIA, Greaves M, Apperley JF, et al. Expression of interleukin-1β and tumour necrosis factor-α in plasma cells from patients with multiple myeloma. Br J Haematol. 2015;104:350–357. doi: 10.1046/j.1365-2141.1999.01193.x
   Web of Science ®Google Scholar
• Trigo FMB, Luizon MR, Dutra HS, et al. Interaction between IL-6 and TNF-α genotypes associated with bacteremia in multiple myeloma patients submitted to autologous stem cell transplantation (ASCT). Leuk Res Rep. 2014;3:76–78.
   PubMedGoogle Scholar
• Wilson AG, Di GF, Blakemore AI, et al. Single base polymorphism in the human tumour necrosis factor alpha (TNF alpha) gene detectable by NcoI restriction of PCR product. Hum Mol Genet. 1992;1:353–353. doi: 10.1093/hmg/1.5.353
   PubMedGoogle Scholar
• Pociot F, D’Alfonso S, Compasso S, et al. Functional analysis of a New polymorphism in the Human TNF α gene Promoter. Scand J Immunol. 1995;42:501–504. doi: 10.1111/j.1365-3083.1995.tb03686.x
   PubMed Web of Science ®Google Scholar